+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache

Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache

Journal of Clinical and Diagnostic Research 10(3): Nc01-Nc04

Topiramate, a sulfa-derivative monosaccharide, is an antiepileptic drug which is administered in the control of migraine. It is reported to cause various ocular side effects such as visual field defect and myopic shift. To investigate the alterations in refractive error, properties of the cornea and changes in the anterior chamber in patients that receive Topiramate for migraine control. This is a hospital-based, non-interventional, observational study that is conducted at Imam Hossein Hospital, affiliated to Shahid Beheshti University of Medical Sciences, Department of Neurology, in collaboration with the department of Ophthalmology. Thirty three consecutive patients with the diagnosis of migraine that were candidate for Topiramate therapy were recruited. Patients with history of ocular trauma or surgery, keratoconus, glaucoma, congenital ocular malformations and any history of unexplained visual loss were excluded. After thorough ophthalmic examination, all the patients underwent central corneal thickness (CCT) measurement, and Pentacam imaging (Scheimpflug camera) at the baseline. Various parameters were extracted and used for analysis. Anterior chamber volume (ACV), anterior chamber depth (ACD), and anterior chamber angle (ACA) measurement was performed. These measurements were repeated on day 30(th) and 90(th) after the initiation of Topiramate therapy. According to the normality tests, parameters with normal distribution were analysed using the repeated measures test and the remaining parameters (with non-normal distribution) were analysed using the non-parametric k-sample test. A p-value< 0.05 was considered statistically significant, according to Bonferroni post hoc correction. There were 66 eyes of 33 patients under the diagnosis of migrainous headache, that Topiramate was initiated for headache control, included in the study. The mean value of refractive error had a statistically significant myopic change, from -0.23 diopters (D) at the baseline to -0.61 D at the 90(th) day of follow-up period (p-value < 0.001). Mean CCT was 531.43 μm at the baseline and increased to 534.72 μm at the 30(th) day, and 537.51 μm at the 90(th) day after the administration of Topiramate (p-value=0.001). Mean value of other parameters, ACV, ACD, and ACA, did not reveal statistically significant change. Myopic shift and gradually increasing CCT in the patients after Topiramate administration should be considered before any refractive surgery. We found no gradual change in the anterior chamber and angle parameters in our patients in the 90 days of follow up. More studies with a longer duration of follow-up are needed to elucidate dose-dependent ocular manifestations.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057808900

Download citation: RISBibTeXText

PMID: 27134906

DOI: 10.7860/JCDR/2016/16263.7339

Related references

Treatment of cluster headache with topiramate: Effects and side-effects in five patients. Cephalalgia 22(3): 186-189, 2002

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 23(1): 69-70; Author Reply 70, 2003

Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 50(1): 77-84, 2010

Migrainous scintillating scotoma and headache is ocular in origin: A new hypothesis. Medical Hypotheses 66(3): 454-460, 2005

Evaluation of headache intensity in migrainous patients with visual handicap through the tactile analogical scale (TAS). Arquivos de Neuro-Psiquiatria 59(3-B): 702-707, 2001

Neuromodulation of late-life migrainous accompaniments with topiramate therapy. Neurology 56(8 Supplement 3): A64, April 24, 2001

Unilateral or "side-locked" migrainous headache with autonomic symptoms linked to night guard use. Headache 48(10): 1537-1539, 2009

Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache 46(9): 1450-1453, 2006

Language Disturbances as Side Effects of Topiramate and Zonisamide Therapy. Epilepsy and Behavior 2(6): 579-584, 2003

Ocular side effects of systemic steroid therapy in renal transplant patients. Annals of Ophthalmology 19(11): 435-437, 1987

Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Therapeutic Advances in Neurological Disorders 6(4): 211-227, 2013

Non-migrainous headache for the evaluation of oral analgesics. British Journal of Clinical Pharmacology 10 Suppl 2: 225s-231s, 1980

An ocular toxicity study with flupirtine as an example of evaluation of possible ocular drug side effects in human volunteers. Klinische Monatsblatter für Augenheilkunde 180(1): 70-74, 1982

Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. Journal of the American Academy of Dermatology 76(2): 201-207, 2017

Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy and Behavior 6(3): 373-381, 2005